Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
Type:
Grant
Filed:
November 14, 2013
Date of Patent:
April 19, 2016
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Andrew J. Murphy, George D. Yancopoulos, Margaret Karow, Lynn Macdonald, Sean Stevens, Aris N. Economides, David M. Valenzuela
Abstract: The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.
Type:
Grant
Filed:
September 28, 2011
Date of Patent:
April 19, 2016
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
James M Wilson, Anna P Tretiakova, Jenny Agnes Greig
Abstract: The present invention relates to the field of cell-based therapeutics. Specifically, the invention is concerned with a composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA for use as a medicament. Moreover, a method for manufacturing a medicament for treating and/or preventing inflammation or a disease or disorder associated therewith comprising the steps of obtaining a macrophage from a sample of said subject, transfecting mRNA encoding IL-10 into said macrophage, and formulating said macrophage in a composition suitable for administration to the said subject, whereby the medicament is manufactured. Finally, a kit is provided for manufacturing such a medicament.
Type:
Grant
Filed:
November 14, 2011
Date of Patent:
April 19, 2016
Assignees:
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG, UNIVERSITÄT ULM
Inventors:
Ziya Kaya, Hugo Katus, Oliver Zimmermann, Wolfgang Rottbauer, Jan Torzewski
Abstract: A dialysis acid precursor assembly including: a dry dialysis acid precursor composition including sodium chloride, a dry acid and a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O), a calcium salt and at least one of a potassium salt, calcium salt and an anhydrous glucose, and a moisture-resistant container having a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dry dialysis acid precursor composition is sealed in the container.
Abstract: The present invention is directed to a transfer resistant and long wear cosmetic composition having a unique gel-like texture with good pickup, payoff, and spreadability properties, as well as a silky smooth feel containing: (a) at least one polyamine; (b) at least one oil-soluble polar modified polymer; (c) water; (d) at least one volatile solvent; (e) at least one non-volatile solvent; (f) at least one water soluble surfactant; (f) at least one colorant; and (g) at least one oil absorbing powder.
Type:
Grant
Filed:
December 16, 2009
Date of Patent:
April 12, 2016
Assignee:
L'OREAL
Inventors:
Hy Si Bui, Mohamed Kanji, Susan Halpern
Abstract: The present invention relates to a method of selecting high producer clones by using an expression vector, the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which polyA has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked. According to the invention, high producer clones can be selected from cell populations at least 10 times fewer than in the existing methods of selecting cell lines. Particularly, high producer clones can be selected using a low concentration of MTX compared to a conventional stepwise gene amplification strategy which comprises carrying out multiple amplification steps while increasing the concentration of MTX.
Type:
Grant
Filed:
March 30, 2010
Date of Patent:
April 12, 2016
Assignee:
CELLTRION INC.
Inventors:
MyungSam Cho, Min Seok Chang, Jong-Mook Kim, HyunJoo Lee, Yoo Cheol Song, ManSu Kim
Abstract: Coronatine has been found to enhance binding of the JAZ1 degron to the Arabidopsis F-box protein COI1, and analysis of the JAZ1 degron sequence has resulted in the identification of specific peptide sequences that bind COI1 with high affinity in the presence of coronatine. Crystal structure analysis has determined that coronatine and JA-Ile enhance the interaction between COI1 and JAZ1 via binding to a specific binding pocket on COI1. Attachment of one or more JAZ1 peptide tags as disclosed herein to a target protein in a non-plant cell expressing Arabidopsis COI1 or a homolog thereof results in degradation of the target protein following addition of a molecule that binds the coronatine/JA-Ile binding pocket on COI1. Therefore, provided herein are compositions, methods, and kits for targeted protein degradation.
Type:
Grant
Filed:
June 8, 2011
Date of Patent:
March 29, 2016
Assignee:
University of Washington
Inventors:
Laura Sheard, Ning Zheng, Ran Brosh, Ihor R. Lemischka
Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
March 22, 2016
Assignee:
Kymab Limited
Inventors:
Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Glenn Friedrich
Abstract: The present invention aims to provide a matrix-type solid preparation that has high-level release controllability for suppressing drug release in the upper gastrointestinal tract and accelerating drug release in the lower gastrointestinal tract, and that solves of all the above drawbacks caused by combining a plasticizer. The present invention provides a method for producing a matrix-type pharmaceutical solid preparation that contains: (a) a methacrylic acid-based enteric polymer; (b) a sugar and/or a sugar alcohol, and (c) tolvaptan.
Abstract: The invention relates to a composite and oral care compositions for use in the mouth to retard the accumulation of dental plaque and/or calculus. The composite is a microaggregate comprising polymer coated, surfactant stabilized particles of a substantially insoluble metal, metal salt or metal oxide, for example zinc oxide. Also methods for retarding the accumulation of dental plaque and/or calculus are provided.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
March 1, 2016
Assignee:
COLGATE-PALMOLIVE COMPANY
Inventors:
Steven Miller, Guofeng Xu, Lin Fei, Ying Yang
Abstract: Genes are expressed by culturing cells comprising a host chromosome comprising an integrated artificial chromosome comprising recombinant genes, under conditions whereby each recombinant gene is expressed copy number dependently and position independently. Deletions increase expression from recombinant gene(s) inserted into the artificial chromosome.
Abstract: The present invention provides for antimicrobial compositions, methods of preparing the antimicrobial compositions, methods of using the antimicrobial compositions, and/or kits that include the antimicrobial compositions. The antimicrobial compositions can be in a dry, solid (e.g., powdered) form, or can be in a liquid (e.g., aqueous) form.
Type:
Grant
Filed:
August 15, 2012
Date of Patent:
February 23, 2016
Assignee:
Medivators Inc.
Inventors:
Thomas M. Gentle, John J. Matta, Adam W. Hauser, Wil Goetsch, Joshua Erickson
Abstract: A liposome comprising a phospholipid, a hydrophobic active comprising a carboxylate group, and a component selected from a group consisting of: a hydrophilic adjuvant comprising a positively charged group, a complex of said hydrophobic active with said hydrophilic adjuvant, and combinations thereof. An aqueous liposome dispersion comprising the liposome, and a personal care composition comprising the liposome. A process of preparing the liposome, comprising the steps of: forming a premix by dissolving a phospholipid, a hydrophobic active comprising a carboxylate group in an organic solvent; evaporating off said organic solvent from the premix to form a phospholipid film; and hydrating said lipid film with a hydration medium comprising a hydrophilic adjuvant comprising a positively charged group and homogenize the medium to form an aqueous liposome dispersion.
Abstract: A topical pharmaceutical composition which is an oil-in-water-oil emulsion comprising a vitamin D derivative or analogue dissolved in a mixture of a non-ionic surfactant and a lower alkanol. The topical pharmaceutical composition may be used in the treatment of dermal conditions, such as psoriasis.
Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
Type:
Grant
Filed:
July 18, 2014
Date of Patent:
January 19, 2016
Assignees:
VIB VZW, Life Sciences Research Partners VZW
Inventors:
Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
Abstract: The present invention includes pH dependent, dry film coating compositions containing calcium silicate for use on orally-ingestible substrates such as tablets and the like. The film coating compositions can be applied as an aqueous suspension either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the polymer is either an enteric or reverse-enteric polymer. Methods of preparing the dry film coatings, methods of preparing corresponding aqueous suspensions, methods of applying the coatings to substrates and the coated substrates themselves are also disclosed.
Type:
Grant
Filed:
February 25, 2014
Date of Patent:
January 12, 2016
Assignee:
BPSI HOLDINGS, LLC
Inventors:
George Reyes, Charles R. Cunningham, Thomas P. Farrell, Cara Young
Abstract: Antimicrobial cleansing compositions are disclosed. The cleansing compositions include thin liquid/foaming compositions and gels. The antimicrobial cleansing compositions are effective antimicrobials and safe for everyday use.
Type:
Grant
Filed:
August 2, 2011
Date of Patent:
January 12, 2016
Assignee:
KIMBERLY-CLARK WORLDWIDE, INC.
Inventors:
Helen Kathleen Moen, Corey Thomas Cunningham, Douglas R. Hoffman, Scott W. Wenzel
Abstract: The present invention concerns a method of agaricidal and microbicidal treatment of textile materials, a Neem oil microcapsule composition specifically for said treatment and a bioactive textile material obtained. More particularly, the present invention concerns the industrial and commercial areas of the treatment of fabrics and like products and is of particular application to textile materials produced from natural fibers such as cotton, feathers or down, or synthetic fibers such as polyester, nylon, acrylic or the like, or mixed fibers such as polyester-cotton. The present invention concerns a method of agaricidal and microbicidal treatment of a textile material, in which microcapsules containing Neem oil are fixed on said textile material.
Abstract: The present invention relates to a patch for the transdermal release of diclofenac or a pharmaceutically acceptable salt thereof, in particular diethylamine salt, and thiocolchicoside.